Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Most traditional or "legacy" insurance products fail to provide sufficient coverage for certain risk exposures vis-à-vis the 3D printing industry, just as they fail to adequately protect businesses in other emerging industries that, along with their concomitant risks, simply did not exist when the legacy insurance products covering them were formulated.
In an industry predicated on stability and predictability, new industries and technologies test industry tolerances and procedures. When loss occurs, policyholders in new or evolving industries often discover — by chance — gaps in the coverage offered by their legacy products, leading to costly disputes with their insurers. For example, 3D printing has evolved from emerging risk to manufacturing staple. As the industry grows however, it faces increased risk exposures including professional liability, products liability, workers’ compensation and employers liability, business interruption and supply chain risks, intellectual property challenges, and, like all businesses, an increasing cyber risk. However, most traditional or “legacy” insurance products fail to provide sufficient coverage for these risk exposures vis-à-vis the 3D printing industry, just as they fail to adequately protect businesses in other emerging industries that, along with their concomitant risks, simply did not exist when the legacy insurance products covering them were formulated.
*May exclude premium content
By Steven P. Benenson
In the past several years, plaintiffs’ firms have threatened or brought class actions against different companies under New Jersey’s Truth-in-Consumer Contract Warranty and Notice Act (TCCWNA). Here's what you need to know.
By Mitch Warnock
When you take a catastrophic injury case involving paralysis, it is important to have a thorough understanding of the problems and pitfalls. In this article, the author explores, from personal experience, the different types of future expenses the client can expect to incur.
By Shannon E. McClure and Whitney Mayer
The FDA’s recent approval of 23andMe’s direct-to-consumer genetic test to identify genes associated with 10 common diseases and disorders could result in a widespread expansion of patients armed with individualized health information. This expansion of genetic information in the hands of consumers potentially impacts regulatory and litigation issues for pharmaceutical companies.
Discussion of major rulings out of Texas and California.